{"product_id":"practical-lipid-management-isbn-9780470056905","title":"Practical Lipid Management","description":"\u003cp\u003eLipid management is a key part of medical practice, affecting the prevention and treatment of several diseases, including diabetes, cardiovascular disease and stroke. A practical text on the clinical management of dyslipidemias, \u003ci\u003ePractical Lipid Management\u003c\/i\u003e balances conceptual development and pathophysiology with a straightforward approach to the identification and treatment of abnormalities in lipid metabolism.\u003c\/p\u003e \u003cp\u003eThe book explores the role of novel risk markers in clinical practice, summarizes the current guidelines for lipid management, and offers a critical and systematic approach to interpreting the results of clinical trials. A feature of the book is a set of sidebars which explore current controversies and unanswered questions in clinical lipidology. The treatment of specific dyslipidemias is illustrated with case studies. Treatment algorithms are also provided.\u003c\/p\u003e \u003cp\u003e\u003ci\u003ePractical Lipid Management\u003c\/i\u003e:\u003c\/p\u003e \u003cul\u003e \u003cli\u003edetails the relationship between specific lipids, lipoproteins and cardiovascular disease,\u003c\/li\u003e \u003cli\u003eprovides guidance on the etiology and diagnosis of lipid abnormalities,\u003c\/li\u003e \u003cli\u003esummarizes current understanding of atherogenesis, and\u003c\/li\u003e \u003cli\u003ereviews the evidence base for the use of therapeutic lifestyle change and specific lipid-lowering medications to reduce morbidity and mortality from cardiovascular disease.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003e\u003ci\u003ePractical Lipid Management\u003c\/i\u003e provides a concise summary of best practice according to various international guidelines, making it a useful tool for all primary care physicians and others involved in the management of diseases such as diabetes, cardiovascular disease and stroke. It will serve as an evidence-based, rapid, and valuable resource for family physicians, internists, nurse practitioners, physician assistants, cardiologists, endocrinologists and allied health professionals involved in the care of patients with lipid disorders.\u003c\/p\u003e  \u003cb\u003eForeword.\u003c\/b\u003e  \u003cp\u003e\u003cb\u003ePreface.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eAcknowledgements.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 1 \u003cb\u003eEpidemiology of Lipids, Lipid Management and Risk for Coronary Heart Disease: An Overview.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1.1 \u003ci\u003eEarly History of Cardiovascular Epidemiology.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.2 \u003ci\u003eLipid Risk Factors are Central to Efforts at CHD Prevention.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.3 \u003ci\u003eLDL-C and CHD Risk.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.4 \u003ci\u003eLDL-C Lowering and CHD Risk Reduction.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.5 \u003ci\u003eOther Atherogenic Lipoproteins: Atherogenic Remnants.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.6 \u003ci\u003eHDL-C and CHD Risk.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.7 \u003ci\u003eTrends in Lipids and Lipid Management in the USA.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.8 \u003ci\u003eThe National Cholesterol Education Program Evaluation Project Using Novel E-Technology (NEPTUNE) II Survey.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eControversy: Should a Measure of Atherogenic Lipoprotein Particle Number be used in Risk Assessment And\/Or to Evaluate the Response to Lipid Therapy?\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 2 \u003cb\u003eVascular Biology and Atherogenesis.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e2.1 \u003ci\u003eIntroduction.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.2 \u003ci\u003eArterial Structure.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.3 \u003ci\u003eEndothelial Cell Function and Dysfunction.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.4 \u003ci\u003eThe Role of Monocytes and Lymphocytes.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.5 \u003ci\u003eAtheromatous Plaques.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 3 \u003cb\u003eDetection, Evaluation, and Treatment Goals for Lipid Disorders in Adults.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e3.1 \u003ci\u003eMatching Aggressiveness of Treatment to Absolute Risk.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.2 \u003ci\u003eScreening for Dyslipidemias.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.3 \u003ci\u003eRisk Stratification.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.4 \u003ci\u003eSteps in the Risk Stratification Process – Major Risk Categories.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.5 \u003ci\u003eTips for Calculating the Framingham Risk Score.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.6 \u003ci\u003eSubcategories for Consideration ofMore Aggressive Optional Treatment Goals.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.7 \u003ci\u003eVery High Risk Patients, Optional LDL-C Goal \u0026lt;70 mg dl\u003c\/i\u003e−1 40.\u003c\/p\u003e \u003cp\u003e3.8 \u003ci\u003eModerately High Risk Patients, OPTIONAL LDL-C Goal \u0026lt;100 mg dl\u003c\/i\u003e−1 40.\u003c\/p\u003e \u003cp\u003e3.9 \u003ci\u003eTreatment Goals for Patients with Elevated Triglycerides.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.10 \u003ci\u003eTriglycerides and HDL-C as Targets for Therapy.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eControversy: Should Treatment Guidelines Include Targets for the Total\/HDL Cholesterol Ratio?\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 4 \u003cb\u003eTherapeutic Lifestyle Changes in the Management of Lipid Disorders and the Metabolic Syndrome.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e4.1 \u003ci\u003eNature and Nurture in the Development of CHD Risk Factors.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.2 \u003ci\u003eLifestyle Factors as Determinants of CHD Risk in Populations.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.3 \u003ci\u003eWithin Country Variations in Lifestyle and CHD Risk.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.4 \u003ci\u003eThe Metabolic Syndrome.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.5 \u003ci\u003eTherapeutic Lifestyle Changes.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.6 \u003ci\u003eThe TLC Diet.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.7 \u003ci\u003eDietary Adjuncts: Viscous Fibers and Plant Sterol\/Stanol Products.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.8 \u003ci\u003ePhysical Activity and Weight Reduction.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.9 \u003ci\u003eSmoking Cessation.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.10 \u003ci\u003eImportance of Allied Health Professionals.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 5 \u003cb\u003eManagement of Elevated Low-Density Lipoprotein Cholesterol.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e5.1 \u003ci\u003eRelationship between LDL-C and Risk for Cardiovascular Events.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.2 \u003ci\u003eClinical Trial Support for Very Aggressive LDL-C Reduction for Those at Highest Risk.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.3 \u003ci\u003eGenetic Disorders Associated with Elevated LDL-C.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.4 \u003ci\u003eAtherogenic Impact of LDL-C.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.5 \u003ci\u003eManagement of Elevated LDL-C.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eControversy: How Low Should We Go?\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eControversy: Risks and Benefits of High-Dose Statin Therapy Versus Combination Lipid Drug Therapy.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eControversy: Do the Benefits of Low-Density Lipoprotein Cholesterol Reduction Depend Strictly on “How Low You Go” or also on “How You Get There”?\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 6 \u003cb\u003eManagement of Elevated Triglycerides and Non-High-Density Lipoprotein Cholesterol.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e6.1 \u003ci\u003eClinical Factors Associated with Elevated TG and Non- HDL-C Levels.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.2 \u003ci\u003eDisorders of TG-Rich Lipoprotein Clearance.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.3 \u003ci\u003eInsulin Resistance and Hypertriglyceridemia.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.4 \u003ci\u003eExcessive Production of VLDL: The Primary Lipid Abnormality in the Insulin-Resistant State.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.5 \u003ci\u003eReasons for Elevated Free Fatty Acid Levels in Insulin- Resistant States.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.6 \u003ci\u003eBody Fat Distribution and Insulin Resistance.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.7 \u003ci\u003eInsulin Resistance in the Nonobese Patient.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.8 \u003ci\u003eHypertriglyceridemia and the Development of Atherogenic Dyslipidemia.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.9 \u003ci\u003eLifestyle Management for the Metabolic Syndrome and Atherogenic Dyslipidemia.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.10 \u003ci\u003eDrug Therapies.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.11 \u003ci\u003eIntensification of Efforts to Lower LDL-C as a Means of Achieving the Non-HDL-C Goal.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.12 \u003ci\u003eTargeting Triglyceride-Rich Lipoprotein Reduction as a Means of Achieving Non-HDL-C Goal.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.13 \u003ci\u003eFibrates.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.14 \u003ci\u003eNiacin.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.15 \u003ci\u003eOmega-3 Fatty Acids.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.16 \u003ci\u003eManagement of Diabetic Dyslipidemia.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eControversy: Do we Need a Triglyceride Treatment Target to Insure a Predominance of Larger, More Buoyant LDLParticles?\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 7 \u003cb\u003eManagement of Depressed High-Density Lipoprotein Cholesterol.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e7.1 \u003ci\u003eThe Relationship between HDL and Risk For CVD.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.2 \u003ci\u003ePrevalence of Low HDL-C.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.3 \u003ci\u003eGoals for HDL Treatment.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.4 \u003ci\u003eAntiatherogenic Effects of HDL.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.5 \u003ci\u003eHDL and Insulin Resistance.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.6 \u003ci\u003eEffects of Lifestyle Modification on Serum HDL.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.7 \u003ci\u003ePharmacologic Management of Low HDL.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eControversy: Do we Need HDL Treatment Goals?\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 8 \u003cb\u003eLipid Management in Population Subsets: Women, the Elderly, Ethnic Minorities, Children, and Adolescents.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e8.1 \u003ci\u003eWomen.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.2 \u003ci\u003eLipids in Women.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.3 \u003ci\u003eTreatment of Dyslipidemia in Women.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.4 \u003ci\u003eSex Hormone Therapy, Lipids, and Cardiovascular Risk in Menopausal Women.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.5 \u003ci\u003eThe Elderly.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.6 \u003ci\u003eSpecial Considerations for LipidManagement in the Elderly.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.7 \u003ci\u003eEthnic Minorities.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.8 \u003ci\u003eRisk Factor Incidence and Prevalence in Ethnic Minority Groups.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.9 \u003ci\u003eChildren and Adolescents.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 9 \u003cb\u003eEmerging Risk Factors and Biomarkers of Cardiovascular Disease.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e9.1 \u003ci\u003eRole of Inflammation in the Pathogenesis of Atherosclerosis.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.2 \u003ci\u003eBiomarkers of Cardiovascular Disease.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 10 \u003cb\u003eA Primer on Clinical Trials and Critical Review of Clinical Trial Reports for the Clinician.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e10.1 \u003ci\u003eDesign Issues Affecting the Validity and Generalizability of Clinical Trial Results.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.2 \u003ci\u003eChance, Bias, and Confounding as Potential Explanations for Trial Results.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.3 \u003ci\u003eEfficacy versus Effectiveness.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.4 \u003ci\u003eUseful Questions to ask when Evaluating a Published Clinical Trial Report.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 11 \u003cb\u003eCase Studies.\u003c\/b\u003e\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e\u003cb\u003eIndex.\u003c\/b\u003e\u003c\/p\u003e \"This is an essential book for physicians who manage patients with lipid disorders. There is no comparable book that provides the depth of information this one does while remaining practical in approach.\" (\u003ci\u003eDoody's\u003c\/i\u003e, September 2009) \u003cp\u003e\u003cb\u003ePeter P. Toth\u003c\/b\u003e, M.D., Ph.D., FAAFP, FICA, FAHA, FACC. Director of Preventive Cardiology, Sterling Rock Falls Clinic, Ltd., Illinois, USA; Chief of Medicine, CGH Medical Center, Illinois, USA; Visiting Clinical Associate Professor, University of Illinois School of Medicine, USA; Editor-in-Chief, \u003ci\u003eJournal of Applied Research?in Clinical and Experimental Therapeutics\u003c\/i\u003e.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eKevin C. Maki,\u003c\/b\u003e PhD. President, Provident Clinical Research \u0026amp; Consulting, Inc., USA.\u003c\/p\u003e \u003cp\u003eA practical text on the clinical management of dyslipidemias, \u003ci\u003ePractical Lipid Management\u003c\/i\u003e balances conceptual development and pathophysiology with a straightforward approach to the identification and treatment of abnormalities in lipid metabolism.\u003c\/p\u003e \u003cp\u003eThe book explores the role of novel risk markers in clinical practice, summarizes the current guidelines for lipid management, and offers a critical and systematic approach to interpreting the results of clinical trials. A feature of the book is a set of sidebars which explore current controversies and unanswered questions in clinical lipidology. The treatment of specific dyslipidemias is illustrated with case studies. Treatment algorithms are also provided.\u003c\/p\u003e \u003cp\u003e\u003ci\u003ePractical Lipid Management\u003c\/i\u003e:\u003c\/p\u003e \u003cul\u003e \u003cli\u003edetails the relationship between specific lipids, lipoproteins and cardiovascular disease\u003c\/li\u003e \u003cli\u003eprovides guidance on the etiology and diagnosis of lipid abnormalities\u003c\/li\u003e \u003cli\u003esummarizes current understanding of atherogenesis\u003c\/li\u003e \u003cli\u003ereviews the evidence base for the use of therapeutic lifestyle change and specific lipid-lowering medications to reduce morbidity and mortality from cardiovascular disease\u003c\/li\u003e \u003cli\u003eincludes a cutting edge discussion of the controversies arising from the results of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) Trial\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003e\u003ci\u003ePractical Lipid Management\u003c\/i\u003e provides a concise summary of best practice according to various international guidelines, making it a useful tool for all primary care physicians and others involved in the management of diseases such as diabetes, cardiovascular disease and stroke. It will serve as an evidence-based, rapid, and valuable resource for family physicians, internists, nurse practitioners, physician assistants, cardiologists, endocrinologists and allied health professionals involved in the care of patients with lipid disorders.\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47989832909029,"sku":"NP9780470056905","price":88.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780470056905.jpg?v=1761785615","url":"https:\/\/k12savings.com\/products\/practical-lipid-management-isbn-9780470056905","provider":"K12savings","version":"1.0","type":"link"}